General Information of Drug (ID: DMM8FUT)

Drug Name
CPU-228 Drug Info
Synonyms Dofetilide analog (cardiac failure), China Pharmaceutical University
Indication
Disease Entry ICD 11 Status REF
Cardiac failure BD10-BD13 Investigative [1]
Cross-matching ID
PubChem CID
10025495
CAS Number
CAS 446877-42-5
TTD Drug ID
DMM8FUT
VARIDT Drug ID
DR01115

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ARC029 DMYNJHI Alzheimer disease 8A20 Phase 3 [6]
SIPATRIGINE DMMQ4GC Neurological disorder 6B60 Discontinued in Phase 2 [7]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [8]
TH-9229 DMG1MPD Reperfusion injury ND56.Z Terminated [9]
CGS-27830 DM8TLY3 N. A. N. A. Terminated [10]
PD-32577 DMBA15J Discovery agent N.A. Investigative [11]
(-)-(S)-BayK8644 DMEA9KH Discovery agent N.A. Investigative [3]
CV-4093 DM983QP Discovery agent N.A. Investigative [6]
[3H](+)-isradipine DM7QE1J Discovery agent N.A. Investigative [12]
MEBUDIPINE DM0P59E Discovery agent N.A. Investigative [13]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flunarizine DMZU5JP Migraine 8A80 Approved [14]
XEN007 DMNKV3O Migraine 8A80 Phase 1 [14]
TH-9229 DMG1MPD Reperfusion injury ND56.Z Terminated [9]
omega-conotoxin GVIA DM4BQFW Discovery agent N.A. Investigative [15]
Alpha-eudesmol DMYSCQU Discovery agent N.A. Investigative [16]
Drug Name Drug ID Indication ICD 11 Highest Status REF
LOMERIZINE DME0TC8 Migraine 8A80 Approved [17]
Ziconotide DMSLJP4 Pain MG30-MG3Z Approved [18]
Hesperidin DMI5DW1 Vascular purpura 3B60 Approved [19]
Cilnidipine DM1975O High blood pressure BA00 Phase 3 [20]
Ralfinamide DMUNMY0 Neuropathic pain 8E43.0 Phase 3 [21]
CNV-2197944 DMLT7JV Pain MG30-MG3Z Phase 2 [22]
Ritanserin DM0X36Y Anxiety disorder 6B00-6B0Z Discontinued in Phase 3 [23]
CNSB-004 DMHAI0M Pain MG30-MG3Z Preclinical [24]
TH-9229 DMG1MPD Reperfusion injury ND56.Z Terminated [9]
PD-157667 DM61NFD N. A. N. A. Terminated [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RAUWOLFIA SERPENTINA ROOT DMWTVAN Discovery agent N.A. Approved [25]
ARC029 DMYNJHI Alzheimer disease 8A20 Phase 3 [6]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [26]
NIGULDIPINE DMSPWMF N. A. N. A. Terminated [25]
TH-9229 DMG1MPD Reperfusion injury ND56.Z Terminated [9]
CGS-27830 DM8TLY3 N. A. N. A. Terminated [10]
R-56865 DMYTI3J Angina pectoris BA40 Terminated [27]
PD-32577 DMBA15J Discovery agent N.A. Investigative [11]
(-)-(S)-BayK8644 DMEA9KH Discovery agent N.A. Investigative [2]
CORYNANTHEINE DM18CUZ Discovery agent N.A. Investigative [25]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
TH-9229 DMG1MPD Reperfusion injury ND56.Z Terminated [9]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) TTZIFHC CAC1C_HUMAN Modulator [2]
Voltage-gated calcium channel alpha Cav1.3 (CACNA1D) TT7RGTM CAC1D_HUMAN Modulator [3]
Voltage-gated calcium channel alpha Cav2.1 (CACNA1A) TTX4QDJ CAC1A_HUMAN Modulator [4]
Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) TT4FDG6 CAC1B_HUMAN Modulator [5]
Voltage-gated calcium channel alpha Cav2.3 (CACNA1E) TTYRP0M CAC1E_HUMAN Modulator [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 534).
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 529).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 530).
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 532).
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 533).
6 Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem. 1989 Oct;32(10):2399-406.
7 Synthesis and characterization of N-(acenaphth-5-yl)-N'-(4-methoxynaphth-1-yl)guanidine as a glutamate release inhibitor and potential anti-ischemic agent, Bioorg. Med. Chem. Lett. 5(19):2259-2262 (1995).
8 Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine. J Med Chem. 1995 May 12;38(10):1579-81.
9 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159)
10 CGS 27830, a potent nonpeptide endothelin receptor antagonist, Bioorg. Med. Chem. Lett. 3(10):2099-2104 (1993).
11 Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
12 alpha 1D (Cav1.3) subunits can form l-type Ca2+ channels activating at negative voltages. J Biol Chem. 2001 Jun 22;276(25):22100-6.
13 Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2. Bioorg Med Chem. 2010 May 1;18(9):3147-58.
14 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
15 Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. J Biol Chem. 2000 Nov 10;275(45):35335-44.
16 Alpha-eudesmol, a P/Q-type Ca(2+) channel blocker, inhibits neurogenic vasodilation and extravasation following electrical stimulation of trigeminal ganglion. Brain Res. 2000 Aug 4;873(1):94-101.
17 Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Feb 1;17(3):662-7.
18 Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84.
19 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
20 N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000.
21 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
22 Clinical pipeline report, company report or official report of Convergence Pharmaceuticals Ltd.
23 N,N-dialkyl-dipeptidylamines as novel N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Mar 22;9(6):907-12.
24 CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med. 2010 Feb;11(2):262-73.
25 Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
26 Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
27 Novel calcium antagonists with both calcium overload inhibition and antioxidant activity. 1. 2-(3, 5-di-tert-butyl-4-hydroxyphenyl)-3-(aminopropyl)... J Med Chem. 1998 Oct 22;41(22):4309-16.